Capital International Investors
CERE

Capital International Investors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Capital International Investors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-253,495
Closed -$10.7M – 470
2024
Q1 		$10.7M Sell
253,495
-610,291
-71% -$25.6M ﹤0.01% 398
2023
Q4 		$36.6M Buy
+863,786
New +$24.8M 0.01% 346

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Capital International Investors's CERE Position: Q2 2024 in Review

Capital International Investors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2024, closing a stake of 253,495 shares — an estimated $10.7M sold.

Capital International Investors first reported a position in CERE in Q4 2023 and held it in 2 quarters. The position peaked at $36.6M in Q4 2023. 231 funds tracked by Wall St. Rank hold CERE as of Q2 2024.

  • Capital International Investors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Capital International Investors sold 253,495 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2024, an estimated $10.7M.
  • Capital International Investors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 2 quarters.
  • Capital International Investors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $36.6M in Q4 2023.
  • 231 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2024.

Based on Capital International Investors's 13F filing for Q2 2024, filed 13 Aug 2024.